Skip to content

Magnetic Seizure Therapy and modified electroconvulsive therapy for the efficacy and impact on cognitive function in adolescents with treatment-resistant depression

Magnetic Seizure Therapy and modified electroconvulsive therapy for the efficacy and impact on cognitive function in adolescents with treatment-resistant depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098032
Enrollment
Unknown
Registered
2025-02-28
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

MST group:The MST group received MST treatment three times a week for 4 weeks on the basis of routine antidepressant drug treatment.
MECT group:The MECT group received MST treatment three times a week for 4 weeks on the basis of routine antidepressant drug treatment.
control group:conventional drug therapy/treatment

Sponsors

Shandong Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1) Inpatients of a specialized hospital in Shandong Province, aged 13 - 18 years old; 2) Voluntarily consent to receive treatment and research procedures; 3) Meet the diagnostic criteria for major depressive disorder in ICD - 11; 4) Meet the criteria for treatment - resistant depression, with no symptom improvement after adequate dosage and full - course treatment with two or more antidepressants; 5) Baseline CDI score >= 19 (for those aged 13 - 17) or HAMD - 17 >= 17 (for those over 17); 6) Be suitable for convulsive treatment; 7) Agree to maintain their current antidepressant treatment interventions; 8) Have no auditory or visual impairment and be able to cooperate in completing the assessment during the interview.

Exclusion criteria

Exclusion criteria: 1.Severe organic brain diseases, such as epilepsy, cerebral hemorrhage, dementia; 2.Complicated with severe somatic diseases, such as cardiovascular diseases, liver and kidney diseases, etc; 3.Patients with contraindications to MECT or MST treatment; 4.Taking benzodiazepine drugs at a dose greater than 2 mg/day of lorazepam or equivalent dose, or any anticonvulsant drugs; 5.Unable to communicate fluently in language to complete neuropsychological tests.

Design outcomes

Primary

MeasureTime frame
Children's Depression Inventory;Beck Depression Inventory ;Hamilton Depression Rating Scale;

Secondary

MeasureTime frame
Montreal Cognitive Assessment (MoCA) form;Global Impression Scale (CGI);

Countries

China

Contacts

Public ContactWang Wei

Shandong Mental Health Center

ken521ww@126.com+86 187 0531 7136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026